Executive Management

Mark Strobeck, Ph.D. is President and Chief Executive Officer at Rockwell Medical. Dr. Strobeck has held leadership positions in both emerging biotechnology and pharmaceutical companies for more than twenty years.

Most recently, he served as Managing Director of Aquilo Partners, LP, a life sciences investment bank. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla’s Chief Business Officer. He served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc.. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P.

Dr. Strobeck has served on the Board of Directors of Windtree Therapeutics, Inc. (Nasdaq:WINT), a biotechnology company focused on developing novel therapies for respiratory diseases, since June 2023. In addition, he currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania.

Tim Chole is Senior Vice President, Chief Commercial Officer at Rockwell Medical. Mr. Chole joined Rockwell in December 2019 as SVP, Sales and Marketing. In November 2022, following the Company's new business strategy announcement, Mr. Chole led Rockwell's commercial organization and supported the Company's vision to focus its efforts on enhancing its revenue-generating businesses and driving the Company towards profitability. Mr. Chole was promoted to Chief Commercial Officer in May 2024.

Mr. Chole has more than 20 years' experience in commercial leadership roles for pharmaceutical and medical device companies. He has a proven track record of success launching products and growing mature portfolios, many of which have been therapeutics or devices for treatment of renal disease. Early in his career, Mr. Chole served as the marketing lead for the IV iron portfolio at Watson Pharmaceuticals (now Allergan), and later was the Global Marketing Director for AKI Therapy at Gambro AB (now Baxter International Inc.). Mr. Chole's background includes global and U.S. marketing leadership and market development roles. Prior to joining Rockwell Medical, Mr. Chole served as the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas.

Mr. Chole received a Bachelor of Science degree in managerial economics from the University of California at Davis.

Heather R. Hunter is Senior Vice President, Chief Corporate Affairs Officer at Rockwell Medical. In this role, Ms. Hunter is responsible for the Company’s investor relations, media relations, communications, branding, government affairs, and patient advocacy. 

Ms. Hunter brings more than two decades of executive leadership, investor relations and communications expertise to Rockwell, with a wealth of experience in the capital markets and a strong network across the financial community. She has a demonstrated track record of success elevating corporate brands, developing and implementing corporate strategy, and driving shareholder value.

Prior to joining Rockwell, Ms. Hunter led communications at Venatorx Pharmaceuticals, a private, pre-commercial anti-infectives pharmaceutical company; Safeguard Scientifics (NYSE:SFE), a growth equity investor focused on early- and growth-stage healthcare and technology companies; and W.P. Carey (NYSE:WPC), one of the largest net lease real estate investment trusts. Ms. Hunter was named to the Philadelphia Business Journal ‘40 Under 40’ list in 2017 and received a B.A. in History from Yale University.

Jesse Neri is Senior Vice President, Chief Financial Officer at Rockwell Medical. With nearly 25 years' experience leading finance functions at both public and private companies, Mr. Neri joined Rockwell Medical in October 2023 as SVP, Finance to oversee all aspects of the Company's finance organization. Prior to joining Rockwell Medical, Mr. Neri was the Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, clinical-stage biopharmaceutical companies that are members of the Roivant portfolio that develop therapeutics to improve the lives of patients with blood disorders and hematological malignancies. Previously, Mr. Neri served as Senior Vice President of Finance at Zyla Life Sciences, a public pharmaceutical company with annual revenue of $80 million. As a member of the senior management team, Mr. Neri was responsible for all aspects of its finance organization including SEC reporting, audit, controllership, and strategic planning. While at Zyla, he played a pivotal role in multiple product acquisitions, financings, commercial product launches and regulatory approvals, along with Zyla's acquisition by Assertio Therapeutics in May 2020. Prior to Zyla, Mr. Neri served as Vice President of Financial Planning and Analysis at Symphony Health Solutions, a private equity-backed market research company with revenue of over $200 million. Mr. Neri received a B.S. in Business Administration of Finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business.

Megan Timmins is Executive Vice President, Chief Legal Officer and Secretary at Rockwell Medical. With over twenty years of legal experience, including six years in the life sciences industry, Ms. Timmins has served in this role at Rockwell since August 2021. Previously, she served as Senior Vice President, General Counsel, and Corporate Secretary at Assertio Holdings, Inc. and Zyla Life Sciences (formerly Egalet Corporation), both publicly traded pharmaceutical companies. Ms. Timmins also held a high-level legal role at Aramark (NYSE: ARMK) as Vice President, Associate General Counsel and Assistant Corporate Secretary. Early in her legal career, she worked in private practice, including with Morgan, Lewis & Bockius, LLP.

Ms. Timmins holds a B.A. from the University of Notre Dame and a J.D. from William and Mary Law School.